These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23529825)

  • 21. Lorcaserin. In obesity: unacceptable risks.
    Prescrire Int; 2014 May; 23(149):117-20. PubMed ID: 24926508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health-related quality of life in randomized controlled trials of lorcaserin for obesity management: what mediates improvement?
    Kolotkin RL; Crosby RD; Wang Z
    Clin Obes; 2017 Dec; 7(6):347-353. PubMed ID: 28815987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial.
    Scirica BM; Bohula EA; Dwyer JP; Qamar A; Inzucchi SE; McGuire DK; Keech AC; Smith SR; Murphy SA; Im K; Leiter LA; Gupta M; Patel T; Miao W; Perdomo C; Bonaca MP; Ruff CT; Sabatine MS; Wiviott SD;
    Circulation; 2019 Jan; 139(3):366-375. PubMed ID: 30586726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An up-to-date evaluation of lorcaserin hydrochloride for the treatment of obesity.
    Tchang BG; Abel B; Zecca C; Saunders KH; Shukla AP
    Expert Opin Pharmacother; 2020 Jan; 21(1):21-28. PubMed ID: 31693425
    [No Abstract]   [Full Text] [Related]  

  • 25. Multicenter, placebo-controlled trial of lorcaserin for weight management.
    Smith SR; Weissman NJ; Anderson CM; Sanchez M; Chuang E; Stubbe S; Bays H; Shanahan WR;
    N Engl J Med; 2010 Jul; 363(3):245-56. PubMed ID: 20647200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lorcaserin Hcl for the treatment of obesity.
    Shukla AP; Kumar RB; Aronne LJ
    Expert Opin Pharmacother; 2015; 16(16):2531-8. PubMed ID: 26472579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 2 new drugs for weight loss.
    Med Lett Drugs Ther; 2012 Sep; 54(1398):69-71. PubMed ID: 22992487
    [No Abstract]   [Full Text] [Related]  

  • 28. Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes.
    Smith SR; O'Neil PM; Astrup A; Finer N; Sanchez-Kam M; Fraher K; Fain R; Shanahan WR
    Obesity (Silver Spring); 2014 Oct; 22(10):2137-46. PubMed ID: 25044799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of lorcaserin for the treatment of obesity.
    Berlie HD; Hurren KM
    Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1053-9. PubMed ID: 23802690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicentre, placebo-controlled trial of lorcaserin for weight management in Chinese population.
    Lu CW; Chang CJ; Yang YC; Lin WY; Huang KC
    Obes Res Clin Pract; 2018 Jul; 12(5):465-471. PubMed ID: 30033356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential.
    Higgins GA; Fletcher PJ; Shanahan WR
    Pharmacol Ther; 2020 Jan; 205():107417. PubMed ID: 31629010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of lorcaserin on cardiometabolic risk factors in overweight and obese patients: A systematic review and meta-analysis.
    Kuo HH; Wang KT; Lee YH; Lin PL; Liu ME; Lin CY; Liu LY
    J Clin Pharm Ther; 2020 Feb; 45(1):35-44. PubMed ID: 31544267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia.
    Nesto R; Fain R; Li Y; Shanahan W
    Postgrad Med; 2016 May; 128(4):364-70. PubMed ID: 27116910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating total and intact GDF-15 levels are not altered in response to weight loss induced by liraglutide or lorcaserin treatment in humans with obesity.
    Valenzuela-Vallejo L; Chrysafi P; Bello-Ramos J; Bsata S; Mantzoros CS
    Metabolism; 2022 Aug; 133():155237. PubMed ID: 35700837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Greenway FL; Fujioka K; Plodkowski RA; Mudaliar S; Guttadauria M; Erickson J; Kim DD; Dunayevich E;
    Lancet; 2010 Aug; 376(9741):595-605. PubMed ID: 20673995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of antiobesity drugs on waist circumference: a mixed treatment comparison.
    Chilton M; Dunkley A; Carter P; Davies MJ; Khunti K; Gray LJ
    Diabetes Obes Metab; 2014 Mar; 16(3):237-47. PubMed ID: 23964810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs.
    Chan EW; He Y; Chui CS; Wong AY; Lau WC; Wong IC
    Obes Rev; 2013 May; 14(5):383-92. PubMed ID: 23331711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lorcaserin for the treatment of obesity.
    Redman LM; Ravussin E
    Drugs Today (Barc); 2010 Dec; 46(12):901-10. PubMed ID: 21589947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Network meta-analysis of lorcaserin and oral hypoglycaemics for patients with type 2 diabetes mellitus and obesity.
    Neff LM; Broder MS; Beenhouwer D; Chang E; Papoyan E; Wang ZW
    Clin Obes; 2017 Dec; 7(6):337-346. PubMed ID: 28891142
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.